Hot topics | Coronavirus pandemic

Caris Life Sciences to Present New Data at ESMO 2021 Highlighting Gene Expression in Colorectal Cancer - Comprehensive Profiling and Clinical Value

Caris Life Sciences to Present New Data at ESMO 2021 Highlighting Gene Expression in Colorectal Cancer - Comprehensive Profiling and Clinical Value

Research finds a strong association between CCR5 and CCL5 gene expression and distinct molecular features including Consensus Molecular Subtype, tumor mutational burden, lymphocyte infiltration in the tumor microenvironment, and These findings, presented at the European Society for Medical Oncology Virtual Congress 2021, show how comprehensive genomic profiling can help treating physicians better utilize targeted therapies to improve patient outcomes.

"We previously reported that genetic polymorphisms in CCL5 and CCR5 genes were significantly associated with treatment outcomes in patients with mCRC receiving anti-angiogenic and antigen-free treatment. We analyzed data from a large clinic-molecular database at Caris Life Sciences, and report if CCR5/CCL5 gene expression is correlated with scalacular features, as well as i This finding suggests that targeting the CCR5/CCL5 axis may have relevant clinical applications in select CRC subgroups, and chemokines CCL5 and CCCL2 may be important targets to modulate

The full results will be presented during the poster display session, the ESMO Virtual Congress 2021. The poster is titled "CCR5/CCL5 Gene Expression in Colorectal Cancer: Comprehensive Profiling and Clinical Value." The address of the poster's poster was "Presentation Number: 454P", "

Additional Presentations Reveal Potential Impact of Precision Medicine Excessive Medicine.

Caris will present additional data from studies demonstrating the critical role of precision medicine and molecular profiling in driving treatment decisions for people with clear-cell renal cell carcinoma and prostate cancer. All presentations will be available online through Caris' website starting Sept. 16.

  • 480P, Gene Expression of NANOG and NANOGP8 in Colorectal Cancer (Presentation Number: 280P) (in the absence of a 240P iP-Anse NANOG is a multi-potent transcription factor that plays resuscitation / eu o l t u. c. role of signaling venom in cancer stemness pathway and This study aimed to clarify molecular characters relating to the gene expression levels of NANOG and NANOGP8 (P8), both of which encode full-length NNOGN protein, in CRC patients.
  • The Embryomic Signatures Associated with Markers of Immune and Angiogenic Sensitivity in Clear-Cell Renal Cell Carcinoma (CCRCC) with Sarcomatoid GEP studies have identified angiogenic and immune signatures with potential predictive value in patients with advanced ccRCC. We aimed to update the results of a large multi-institutional database (Barata, ASCO-GU 21) focused on tumors with sarcomatoid/rhabdoid features.

"It is vital for physicians and patients to get access to next-generation sequencing and molecular assays to determine an optimal treatment path," said W. Michael Korn, M.D., head of Caris Life Sciences "Our data at ESMO 2021 shows how Caris' industry-leading technology and cutting-edge scientific approach provide new insights into cancer biology and guide the development of novel therapeutic strategies, thus pursuing the goal of helping each cancer patient

Caris Life Sciences About Cari Life Science About cari Bio Sciences. Caris Life Sciences is a leading molecular scientist and artificial intelligence, with aims to fulfill the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins, and provides a detailed analysis of the moles that helps physicians and cancer patients make more precise and personalized treatment decisions. A comprehensive analysis of the most relevant DNA and RNA profiling available on the market.

Caris is advancing precision medicine with Caria Artificial Intelligence, along with its proprietary artificial intelligence analytics engine, DEANTM, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, along with mature clinical outcomes on hundreds of thousands of patients, provides unmatched molecular solutions for patients and physicians, payers and biopharmaceutical organizations.

Caris Life Sciences has headquarters in Phoenix, Denver, New York and Basel, Switzerland. Caris provides services across the United States, Europe, Asia and other international markets. To learn more, please visit our website. CarisLifeSciences.com CarsLife Sciences.net is a caris living science site. Follow us on Twitter or if you follow us. @CarisLS @Camisl ) ( ).

Caris Life Sciences Media Contact: Ann Obeney, Ann-Osbourne, is an obeney. [email protected] 469-550-1589

Caris Life Sciences International Support: +4121533 53 00 [email protected] + 412 1533 58 - (e-mail-protection).

Caris Commercial Contact: Ruth Moloney [email protected] [selectric protected].

Caris Medical Contact: Vasanti Natarajan [email protected] [security protected].

SOURCE Caris Life Sciences SURCE SUCCE Life Science SUSCE!

Related Links

http://www.carislifesciences.com/ / www.careerlifescients/.

You may also like: